 |
| Click on image for an enlarged view. |
This morning, I was reading a story in MM&M about the testimony of Turing Pharmaceuticals chief commercial officer Nancy Retzlaff during a recent House hearing on drug pricing, where she attempted to justify the 5,000% price increase on the firm's toxoplasmosis treatment Daraprim.
Retzlaff "defended the dramatic hike in part by noting that the drugmaker provides access through patient assistance programs (PAPs)" (read "Turing Testimony Changes Perception of #Pharma Patient Assistance Programs").
I decided to check out Turing's PAP by visiting www.turingpharma.com where I clicked on the "PRODUCTS" tab, then "Daraprim." I was taken to the page shown on the left (http://www.daraprimdirect.com/patients).
Notice anything unusual?
Read more »
Dear FDA: The Daraprim Website Lacks Some Important Safety Information Patients Should Know About!
Reviewed by admin
on
February 19, 2016
Rating:
Reviewed by admin
on
February 19, 2016
Rating:
No comments: